These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 36297616)

  • 1. Heparin and Heparin-Based Drug Delivery Systems: Pleiotropic Molecular Effects at Multiple Drug Resistance of Osteosarcoma and Immune Cells.
    Todosenko N; Yurova K; Khaziakhmatova O; Malashchenko V; Khlusov I; Litvinova L
    Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low molecular weight heparin modified bone targeting liposomes for orthotopic osteosarcoma and breast cancer bone metastatic tumors.
    Wu H; Luo Y; Xu D; Ke X; Ci T
    Int J Biol Macromol; 2020 Dec; 164():2583-2597. PubMed ID: 32795579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic strategies to overcome taxane resistance in cancer.
    Das T; Anand U; Pandey SK; Ashby CR; Assaraf YG; Chen ZS; Dey A
    Drug Resist Updat; 2021 Mar; 55():100754. PubMed ID: 33691261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
    Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
    J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel nanomedicines to overcome cancer multidrug resistance.
    Su Z; Dong S; Zhao SC; Liu K; Tan Y; Jiang X; Assaraf YG; Qin B; Chen ZS; Zou C
    Drug Resist Updat; 2021 Sep; 58():100777. PubMed ID: 34481195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
    Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
    Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
    Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
    Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAXX is a novel target to overcome resistance to doxorubicin and cisplatin in osteosarcoma.
    Ma W; Yang L; Liu H; Chen P; Ren H; Ren P
    Biochem Biophys Res Commun; 2020 Jan; 521(1):204-211. PubMed ID: 31640855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
    Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
    Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long Non-coding RNAs in Cisplatin Resistance in Osteosarcoma.
    Ferretti VA; León IE
    Curr Treat Options Oncol; 2021 Mar; 22(5):41. PubMed ID: 33745006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
    Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies.
    Hattinger CM; Patrizio MP; Fantoni L; Casotti C; Riganti C; Serra M
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flavonoids Active Against Osteosarcoma: A Review of the Molecular Mechanisms Involved.
    Liu H; Gao Y; Dong Y; Cheng P; Chen A; Huang H
    Curr Pharm Des; 2017; 23(13):1993-2001. PubMed ID: 28201973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-155 mediates drug resistance in osteosarcoma cells via inducing autophagy.
    Chen L; Jiang K; Jiang H; Wei P
    Exp Ther Med; 2014 Aug; 8(2):527-532. PubMed ID: 25009614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding and inhibition of drug transport proteins by heparin: a potential drug transporter modulator capable of reducing multidrug resistance in human cancer cells.
    Chen Y; Scully M; Petralia G; Kakkar A
    Cancer Biol Ther; 2014 Jan; 15(1):135-45. PubMed ID: 24253450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surface engineering of nanoparticles with ligands for targeted delivery to osteosarcoma.
    Huang X; Wu W; Yang W; Qing X; Shao Z
    Colloids Surf B Biointerfaces; 2020 Jun; 190():110891. PubMed ID: 32114271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCN2 enhances resistance to cisplatin-mediating cell apoptosis in human osteosarcoma.
    Tsai HC; Huang CY; Su HL; Tang CH
    PLoS One; 2014; 9(3):e90159. PubMed ID: 24637722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nano-Based Drug Delivery Systems: Potential Developments in the Therapy of Metastatic Osteosarcoma-A Narrative Review.
    Luo Y; Sun M; Tan L; Li T; Min L
    Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140058
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.